We are live on ! Find out more
BLPH

Bellerophon Therapeutics, Inc.
BLPH

Delisted

BLPH was delisted on the 13th of October, 2023.

Back to rankings

22 hedge funds and large institutions have $2.68M invested in Bellerophon Therapeutics, Inc. in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 11 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 22 → 22 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

30% less capital invested

Capital invested by funds: $3.82M → $2.68M (-$1.14M)

73% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 11

Holders
22
Holders Change
–
Holders Change %
0%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
3
Reduced
11
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$15.2K
2
TRCT
Tower Research Capital (TRC)
New York
+$2.09K
3
UBS Group
UBS Group
Switzerland
+$836
4
Citigroup
Citigroup
New York
+$205

Top Sellers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
-$87.4K
2
TI
Telemetry Investments
New York
-$45.7K
3
TSS
Two Sigma Securities
New York
-$35K
4
Millennium Management
Millennium Management
New York
-$31.1K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$23.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$852K -$23.2K -9,763 -3%
Wells Fargo
2
Wells Fargo
California
$472K – – –
Renaissance Technologies
3
Renaissance Technologies
New York
$437K +$15.2K +6,400 +4%
BlackRock
4
BlackRock
New York
$285K -$2.33K -981 -0.8%
TI
5
Telemetry Investments
New York
$197K -$45.7K -19,197 -19%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$137K -$21 -9 -0%
Jane Street
7
Jane Street
New York
$88K -$87.4K -36,733 -50%
Northern Trust
8
Northern Trust
Illinois
$66K -$19.8K -8,313 -23%
State Street
9
State Street
Massachusetts
$50K – – –
Tudor Investment Corp
10
Tudor Investment Corp
Connecticut
$47K – – –
Millennium Management
11
Millennium Management
New York
$26K -$31.1K -13,059 -54%
UBS Group
12
UBS Group
Switzerland
$6K +$836 +351 +16%
Morgan Stanley
13
Morgan Stanley
New York
$5K -$7.84K -3,292 -60%
TRCT
14
Tower Research Capital (TRC)
New York
$4K +$2.09K +878 +126%
US Bancorp
15
US Bancorp
Minnesota
$3K – – –
Osaic Holdings
16
Osaic Holdings
Arizona
$2K – – –
Royal Bank of Canada
17
Royal Bank of Canada
Ontario, Canada
$1K -$5.17K -2,174 -90%
Federated Hermes
18
Federated Hermes
Pennsylvania
$1K -$26 -11 -7%
Northwestern Mutual Wealth Management
19
Northwestern Mutual Wealth Management
Wisconsin
$1K – – –
TSS
20
Two Sigma Securities
New York
– -$35K -11,161 Closed
Bank of America
21
Bank of America
North Carolina
– -$112 -47 -52%
Citigroup
22
Citigroup
New York
– +$205 +86 New

BLPH Hedge Fund Activity: Q1 2022 in Review

22 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q1 2022, worth a combined $2.68M — down 30% from $3.82M a quarter earlier.

Fund positioning in BLPH was balanced in Q1 2022: 1 fund opened new positions, 1 closed out, 3 added to existing stakes and 11 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $15.2K. The largest seller was Jane Street, cutting an estimated $87.4K.

  • 22 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q1 2022, unchanged from Q4 2021.
  • Funds reported $2.68M of Bellerophon Therapeutics, Inc. stock for Q1 2022, down 30% quarter-over-quarter.
  • 1 fund opened new Bellerophon Therapeutics, Inc. positions in Q1 2022 and 1 closed out, a net change of 0 holders.
  • The largest Bellerophon Therapeutics, Inc. buyer in Q1 2022 was Renaissance Technologies, an estimated $15.2K added.
  • The largest Bellerophon Therapeutics, Inc. seller in Q1 2022 was Jane Street, an estimated $87.4K sold.

Based on aggregated 13F filings for Q1 2022.